Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Trial Profile

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Linagliptin (Primary) ; CD26 antigen inhibitors; Sulfonylureas; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Jan 2017 Planned number of patients changed from 500000 to 99999.
    • 16 Jun 2015 Planned number of patients changed from 250000 to 500000 as reported by ClinicalTrials.gov record.
    • 04 Mar 2015 Planned number of patients changed from 200000 to 250000 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top